| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9966 | MK-1064 Featured | MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. |
|
| DC1070 | MK-1775(AZD-1775,Adavosertib) Featured | MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM. |
|
| DC7465 | MK-2206 2HCl Featured | MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
|
| DC8479 | MK-2461 | MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
|
| DC7585 | Omarigliptin Featured | MK-3102 (MSD) is a novel DPP-4 Inhibitor, which improves glycaemic control with low risk of symptomatic hypoglycaemia. |
|
| DC7646 | MK3697 | MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM. |
|
| DC9707 | MK-4101 Featured | MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma. |
|
| DC4179 | Niraparib(MK4827) free base Featured | MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9862 | Niraparib(MK4827) hydrochloride Featured | MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9576 | Niraparib tosylate Featured | MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1. |
|
| DC7466 | MK-5108 | MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM; 220- and 190-fold more selective for Aurora A than Aurora B/C. |
|
| DC9279 | MK-571 Featured | MK-571 is a selective, orally active CysLT1 receptor antagonist. |
|
| DC9448 | MK591 | MK591(Quiflapon sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. |
|
| DC5034 | MK8245 Featured | MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy. |
|
| DC12020 | MK-8722 Featured | MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase. |
|
| DC9901 | Verubecestat (MK-8931) Featured | MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase. |
|
| DC9993 | MK-8998 Featured | MK-8998 is a novel bioactive compound for the treament of psychiatric disease. |
|
| DC9682 | ML-264 Featured | ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5). |
|
| DC10282 | ML385 Featured | ML385 is a novel and specific NRF2 inhibitor. |
|
| DC5086 | Ixazomib(MLN2238) Featured | MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. |
|
| DC12255 | MLN-4760 Featured | MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
|
| DC5176 | Pevonedistat Featured | MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme (NAE) with IC50 of 4 nM. |
|
| DC9365 | MLN8054 Featured | MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B. |
|
| DC5089 | Ixazomib Citrate (MLN-9708) Featured | MLN-9708 is a proteasome inhibitor, which inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome. |
|
| DC3160 | Montelukast Sodium Featured | Montelukast belongs to a group of medications known as leukotriene receptor antagonists. |
|
| DC7200 | Motesanib Diphosphate (AMG-706) Featured | Motesanib (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. |
|
| DC10284 | Motesanib Featured | Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret. |
|
| DC4226 | Moxifloxacin hydrochloride Featured | Moxifloxacin(Avelox, Avalox) is a fourth generation synthetic fluoroquinolone antibacterial agent. |
|
| DC10326 | Mozavaptan | Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM. |
|
| DC7202 | MPC-3100 | MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. |
|
